April, 2017—Two decades of successful investing in some of biotech’s biggest hits has made Jonathan Silverstein rich. Now he is looking for investments that could save his life.
August, 2017—Health care venture capitalist Jonathan Silverstein has more than two decades of professional experience with strategic investment in drug development. However, Jonathan’s sense of urgency to find cures intensified after he received a diagnosis...
August, 2017—The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO Inc. (“REGENXBIO”), and OrbiMed today announced the formation and launch of Prevail Therapeutics, Inc., (“Prevail”), a new company focused on discovering and developing novel biologic...
August, 2017—Regenxbio has joined forces with investment firm OrbiMed and a new nonprofit foundation to create Prevail Therapeutics, a startup focused on new biologics and gene therapies for Parkinson’s disease (PD).
